This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
Uncategorized
What I’m short now
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
361 Degrees update: one red flag too many, time to sell
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
A small-cap COVID beneficiary with major re-rating potential: 60% upside in 12 months
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
This UK FMCG name trades at 7.5x normalized FCF, 75-100% upside in a post-COVID world
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
Quick Metlifecare update: incrementally more bullish post recent developments
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
German small cap update: strap yourself in, the story keeps getting better and better
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
What I’m buying now part 3 – a few juicy bonds
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
Latest thoughts on GCAP/INTL and MET.NZ
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
Endor: 100% revenue growth and explosive long-term trajectory at only 7x EBIT and 10x P/E – this German small-cap should triple (and keep going)
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.